Stockscreener 앱 받기
6.04
1.15%
-0.07
시간 외 거래:
6.04
전일 마감가:
$6.11
열려 있는:
$6.1
하루 거래량:
8,953
Relative Volume:
0.33
시가총액:
$27.24M
수익:
$85.53M
순이익/손실:
$-9.78M
주가수익비율:
-2.7515
EPS:
-2.1952
순현금흐름:
$1.28M
1주 성능:
+1.85%
1개월 성능:
+2.90%
6개월 성능:
+1.96%
1년 성능:
+34.22%
1일 변동 폭
$6.04
$6.28
1주일 범위
$5.90
$6.3206
52주 변동 폭
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
명칭
Harvard Bioscience Inc
전화
(508) 893-8999
주소
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
6.04 | 27.56M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
350.06 | 125.08B | 11.03B | 3.16B | 2.83B | 8.7254 |
BDX
Becton Dickinson Co
|
153.84 | 42.57B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
39.09 | 32.88B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.35 | 34.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
195.80 | 28.81B | 5.54B | 1.52B | 1.74B | 10.37 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | 개시 | Northland Capital | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-01-24 | 재확인 | Janney | Buy |
| 2018-01-23 | 재확인 | The Benchmark Company | Buy |
| 2016-11-17 | 개시 | Singular Research | Buy |
| 2015-07-28 | 개시 | The Benchmark Company | Buy |
모두보기
Harvard Bioscience Inc 주식(HBIO)의 최신 뉴스
HBIO Stock Price, Quote & Chart - ChartMill
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
Harvard Bioscience focuses on life science instruments as investors weigh long-term demand - ad-hoc-news.de
Harvard Bioscience focuses on lab equipment growth - Ad-hoc-news.de
Harvard Bioscience (HBIO) Hovers Near Support Amid Low-Volume TradingBollinger Walk - dars.gov.et
Harvard Bioscience | SD: Specialized disclosure report - Moomoo
Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO) - TradingView
HBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to earnings forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to book forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Enterprise value to EBITDA forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Harvard Bioscience Inc (HBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harvard Bioscience (HBIO) Slips Slightly, Holding Above Support at $5.71Quality Factor - dars.gov.et
Harvard Bioscience holds key trading range, shares between support and resistance - AD HOC NEWS
HBIO News | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill
Harvard Bioscience Inc (HBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harvard Bioscience Inc (HBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harvard Bioscience Inc (HBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 restricted stock units - Stock Titan
Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 RSUs in new grant - Stock Titan
Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs - Stock Titan
HBIO Q1 2026 Earnings: Significant EPS Beat Drives Positive Stock ReactionMid-Term Outlook - dars.gov.et
Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results - Moomoo
Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors - TipRanks
Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases - Stock Titan
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
HBIOHarvard Bioscience Inc Website Traffic and Mobile Apps Usage - Finviz
Harvard Bioscience: HBIO stock stalls, margin pressure in focus - Bez Kabli
HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI
HBIO Q1 2026 Earnings: EPS Surprises to the Upside Despite Challenging QuarterEstimate Dispersion - thelegaladvocate.com
Harvard Bioscience Slips as Traders Assess Support Levels; HBIO Down Nearly 3%Open Trading Community - Newser
Harvard Bioscience (HBIO) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.33Real Trader Insights - Newser
Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story - AD HOC NEWS
Harvard Bioscience, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-05-15 - Seeking Alpha
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts - Investing.com UK
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts By Investing.com - Investing.com Australia
Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake - Stock Titan
Harvard Bioscience Transitions to Translational Science Focus in 2026 - HarianBasis.co
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations - GuruFocus
Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss By Investing.com - Investing.com Nigeria
Harvard Bioscience Q1 2026 Earnings Call Transcript - MarketBeat
Harvard Bioscience Inc (HBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
0.82%
자본화:
|
볼륨(24시간):